XtalPi Holdings Ltd
XtalPi Holdings Ltd is a biotechnology company that develops artificial intelligence (AI)-driven drug discovery platforms and services for pharmaceutical and biotechnology companies.
Business. XtalPi Holdings Ltd (2228.HK) is a healthcare company engaged in the advanced medical equipment and technology industry. The firm operates within the Healthcare Services & Equipment sector, focusing on the development and sale of medical devices. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
XtalPi Holdings Ltd (2228.HK) is a healthcare company engaged in the advanced medical equipment and technology industry. The firm operates within the Healthcare Services & Equipment sector, focusing on the development and sale of medical devices. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
XtalPi's capital structure is characterized by a lack of disclosed balance-sheet inputs, which prevents a full liquidity assessment. The company has no dilution risk in the near term, as shares outstanding for both basic and diluted scenarios are equal at 4.3 billion shares. However, the absence of liquidity metrics and going-concern language in source documents raises uncertainty about the company's short-term financial health.
Profitability and returns are not currently available for analysis due to the absence of valuation snapshot data. The company's performance against industry_config preferred metrics and cohort medians cannot be determined at this time.
XtalPi's revenue is not segmented by geographic region or product line in the available data, so the company's exposure to specific markets or business lines cannot be assessed. The lack of disclosed revenue concentration data prevents an evaluation of geographic or segment risk.
The company's growth trajectory is not quantifiable due to the absence of historical revenue data and outlook numeric deltas. Analysts have provided a mean price target of 11.60 CNY, with a median of 11.60 CNY and a range from 10.80 CNY to 12.40 CNY. The mean recommendation is 1.25, indicating a generally positive outlook from analysts.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet inputs and the absence of going-concern language in source documents. The company is not currently facing significant dilution risk, and no adjustments have been applied to valuation metrics.
Recent events and filings have not been disclosed in the available data, so no specific recent developments can be cited. The company's narrative remains largely based on static profile and classification data.
- XtalPi operates in the Advanced Medical Equipment & Technology industry, focusing on AI-driven drug discovery platforms.
- The company has no near-term dilution risk, with basic and diluted shares outstanding being equal.
- Analysts have a generally positive outlook, with a mean price target of 11.60 CNY and a mean recommendation of 1.25.
- Liquidity risk cannot be assessed due to missing balance-sheet data and lack of going-concern language.
- Revenue concentration and geographic exposure are not disclosed, limiting the ability to assess business risk.
- Growth trajectory and historical performance are not quantifiable due to missing data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥802.6M, +201,2% YoY; Operating income +107,0% YoY.
- ▍Revenue ¥802.6M, +201,2% YoY
- ▍Operating income +107,0% YoY
- ▍Net income +108,2% YoY
- ▍Free cash flow +112,0% YoY
- ▍Net margin 15.4%
Revenue ¥266.4M, +52,8% YoY; Operating income +5,3% YoY.
- ▍Revenue ¥266.4M, +52,8% YoY
- ▍Operating income +5,3% YoY
- ▍Net income +20,8% YoY
- ▍Free cash flow +25,0% YoY
- ▍Net margin -569.2%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,02 |
| Revenue | —no estimate | —no estimate | 951,4M CNY |
| Operating income | —no estimate | —no estimate | -211,3M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- XtalPi Holdings Ltd Market data — financials · 2026-05-26
- XtalPi Holdings Ltd Market data — analyst estimates · 2026-05-26
- XtalPi Holdings Ltd Market data — ESG · 2026-05-26
Ownership & reference
Leadership
- Jian MaChief Executive Officer, Executive Director
- Shuhao WenExecutive Chairman of the Board